Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 6K citations · Full text

Medicine, Nephrology, Pharmacology +17

Animal research: Reporting <i>in vivo</i> experiments: The ARRIVE guidelines

Carol Kilkenny, William J. Browne, Innes C. Cuthill et al. · British Journal of Pharmacology · 2010 · 3.6K citations · Full text

Humanities, Animal Sciences, Laboratory Animal Medicine +16

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17